Program
imatinib
Also written as “Imatinib”, “imatinib mesylate” and “Imatinib mesylate”.
Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Gastrointestinal Stromal Tumors · Pulmonary Arterial Hypertension · Leukemia, Myeloid, Chronic-Phase · Glioblastoma, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 531 open or running | phase 4since Apr 26, 2004 | Jul 5, 2000 | Aug 30, 2030phase 4 · NCT04877522 |
| Exvastat | 20 open or running | phase 2since Jun 29, 2021 | Oct 24, 2017 | none ahead |
| Amneal Pharmaceuticals | 10 open or running | phase 3since Apr 1, 2014 | Apr 1, 2014 | none ahead |
| Dong-A ST | 10 open or running | phase 1since Dec 14, 2012 | Dec 14, 2012 | none ahead |
| HuLow | 10 open or running | phase 1since Nov 16, 2015 | Nov 16, 2015 | none ahead |
| Nurex S.r.l. | 10 open or running | phase 2since Jul 2, 2018 | Jul 2, 2018 | none ahead |
| Samyang Biopharmaceuticals | 10 open or running | phase 1since Dec 27, 2011 | Dec 27, 2011 | none ahead |
| Sino Biopharmaceutical | 10 open or running | phase 4since Dec 11, 2014 | Dec 11, 2014 | none ahead |
Also a collaborator on its studies: icon-clinical-research, ppd-development-lp, q2-solutions, parexel and accutest-research-laboratories-i-pvt-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jul 5, 2000.
- Nov 6, 2011Phase 1 study in 3rd Line GISTNovartis · NCT01468688 · 60 enrolled · United States, Belgium, Canada and more
- Nov 29, 2011Phase 2 study in Gastrointestinal Stromal TumorsNovartis · NCT01483014 · 30 enrolled · Brazil
- Dec 27, 2011Samyang Biopharmaceuticals's first study: phase 1 study in HealthyNew to Samyang BiopharmaceuticalsSamyang Biopharmaceuticals · NCT01504984 · 30 enrolled · Korea, Republic of
- Nov 28, 2012Phase 4 study in Gastrointestinal Stromal TumorsNovartis · NCT01742299 · 155 enrolled · United States, China, Finland and more
- Dec 14, 2012Dong-A ST's first study: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNew to Dong-A STDong-A ST · NCT01751919 · 37 enrolled · Korea, Republic of
- Jan 17, 2014Phase 3 study in Pulmonary Arterial HypertensionNovartis · NCT02042014 · 8 enrolled · Japan
- Apr 1, 2014Amneal Pharmaceuticals's first study: phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNew to Amneal PharmaceuticalsAmneal Pharmaceuticals · NCT02103322 · 48 enrolled · India
- Dec 11, 2014Sino Biopharmaceutical's first study: phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT02317159 · 90 enrolled
- Nov 16, 2015HuLow's first study: phase 1 study in Malaria, FalciparumNew to HuLowHuLow · NCT02614404 · 15 enrolled · Vietnam
- Oct 24, 2017Exvastat's first study: phase 1 study in Acute Lung InjuryNew to ExvastatExvastat · NCT03328117 · 47 enrolled · United Kingdom
- Jun 15, 2018Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT03578367 · 104 enrolled · United States, Austria, Canada and more
- Jul 2, 2018Nurex S.r.l.'s first study: phase 2 study in Malaria, FalciparumNew to Nurex S.r.l.Nurex S.r.l. · NCT03697668 · 50 enrolled · Vietnam
- May 4, 2021Phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT04877522 · 347 planned · United States, Argentina, Austria and more
- Jun 29, 2021Phase 2 study in Respiratory Distress SyndromeExvastat · NCT04953052 · India
Ahead
- Aug 30, 2030Primary completion: phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNovartis · NCT04877522
TargetBeta
“Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor; Bcr/Abl fusion protein inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 61 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT04953052Respiratory Distress Syndrome · India | 2 | Withdrawn | Exvastat | Aug 31, 2022 | 0 |
| NCT04877522Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Austria and more | 4 | Recruiting | Novartis | Aug 30, 2030 | 347 |
| NCT03697668Malaria, Falciparum · Vietnam | 2 | UNKNOWN | Nurex S.r.l. | Dec 31, 2018 | 50 |
| NCT03578367Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Austria, Canada and more | 2 | Completed | Novartis | Nov 8, 2021 | 104 |
| NCT03328117Acute Lung Injury · United Kingdom | 1 | Completed | Exvastat | Mar 5, 2018 | 47 |
| NCT02614404Malaria, Falciparum · Vietnam | 1 | Completed | HuLow | Dec 2, 2016 | 15 |
| NCT02317159Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | UNKNOWN | Sino Biopharmaceutical | Jun 2017 | 90 |
| NCT02103322Leukemia, Myelogenous, Chronic, BCR-ABL Positive · India | 3 | Completed | Amneal Pharmaceuticals | Mar 2014 | 48 |
| NCT02042014Pulmonary Arterial Hypertension · Japan | 3 | Completed | Novartis | Oct 17, 2016 | 8 |
| NCT01751919Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Korea, Republic of | 1 | Completed | Dong-A ST | Aug 2012 | 37 |
| NCT01742299Gastrointestinal Stromal Tumors · United States, China, Finland and more | 4 | Completed | Novartis | Apr 20, 2026 | 155 |
| NCT01504984Healthy · Korea, Republic of | 1 | Completed | Samyang Biopharmaceuticals | Apr 2012 | 30 |
| NCT01483014Gastrointestinal Stromal Tumors · Brazil | 2 | Completed | Novartis | Jan 2012 | 30 |
| NCT014686883rd Line GIST · United States, Belgium, Canada and more | 1 | Completed | Novartis | Jul 29, 2016 | 60 |
| NCT01392495Pulmonary Arterial Hypertension · United States, Australia, Belgium and more | 3 | Terminated | Novartis | Mar 2014 | 17 |
| NCT01392469Pulmonary Arterial Hypertension · United States, Australia, Belgium and more | 3 | Completed | Novartis | Oct 25, 2012 | 21 |
| NCT01316458Prostatic Neoplasms · Germany | 2 | Completed | Novartis | Jul 2010 | 51 |
| NCT01271166Neoplasms · Australia | 1 | Terminated | Novartis | Aug 2009 | 10 |
| NCT01216085CML · Korea, Republic of | 2 | Completed | Novartis | Jul 2011 | 10 |
| NCT01172548Gastrointestinal Stromal Tumors · Algeria, Egypt, India and more | 2 | Completed | Novartis | Mar 2014 | 132 |
| NCT01117987Pulmonary Arterial Hypertension · United States, Austria, Belgium and more | 3 | Terminated | Novartis | Apr 2014 | 144 |
| NCT01066468Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Russian Federation | 1 | Terminated | Novartis | May 2011 | 3 |
| NCT00940563Advanced Gastrointestinal Stromal Tumors · Italy | 2 | Completed | Novartis | Aug 2004 | 135 |
| NCT00902174Pulmonary Arterial Hypertension · United States, Austria, Belgium and more | 3 | Completed | Novartis | May 2011 | 202 |
| NCT00867113Gastrointestinal Stromal Tumors · United States | 2 | Completed | Novartis | Dec 20, 2016 | 91 |
| NCT00613171Scleroderma, Systemic · United States, Germany, Italy and more | 2 | Completed | Novartis | Jan 13, 2010 | 27 |
| NCT00510354Progressive Gastrointestinal Stromal Tumor · Germany | 4 | Completed | Novartis | Nov 2012 | 28 |
| NCT00477269Pulmonary Arterial Hypertension · United States, Austria, Germany and more | 3 | Completed | Novartis | Jan 2014 | 59 |
| NCT00471497Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Austria and more | 3 | Completed | Novartis | Sep 2, 2009 | 846 |
| NCT00441155Gastrointestinal Stromal Tumors · United States, France, Italy | 1 | Completed | Novartis | Jan 2011 | 14 |
| NCT00428909Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Korea, Republic of | 1 | Completed | Novartis | Aug 2008 | 12 |
| NCT00427583Neurofibrosarcoma · Germany | 3 | Terminated | Novartis | Apr 2009 | 11 |
| NCT00426179Rhinitis, Allergic, Seasonal · United Kingdom | 2 | Completed | Novartis | 30 | |
| NCT00422825Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | Completed | Novartis | Sep 2006 | 16 |
| NCT00420043Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | Completed | Novartis | Nov 2006 | 32 |
| NCT00417807Refractory Desmoplastic Small Round Cell Tumors · Italy | 2 | Completed | Novartis | Jun 2009 | 9 |
| NCT00372476Breast Neoplasms · Germany | 4 | Completed | Novartis | Jul 2012 | 33 |
| NCT00333840Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, Austria and more | 3 | Completed | Novartis | Mar 2012 | 1,106 |
| NCT00290771Glioblastoma · United States | 2 | Terminated | Novartis | Aug 2008 | 231 |
| NCT00237185Gastrointestinal Stromal Tumors · United States, Australia, Finland | 2 | Completed | Novartis | Jun 2013 | 148 |
| NCT00237172Gastrointestinal Stromal Tumors | 2 | Completed | Novartis | Jul 2005 | 72 |
| NCT00237120Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | Completed | Novartis | 100 | |
| NCT00171977Gastrointestinal Stromal Tumors · Japan | 4 | Completed | Novartis | Apr 2009 | 64 |
| NCT00171938Glioblastoma · Brazil | 2 | Terminated | Novartis | Jun 2006 | 30 |
| NCT00171912Hypereosinophilic Syndrome · Australia | 2 | Completed | Novartis | Jan 2012 | 38 |
| NCT00171899Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Canada | 4 | Completed | Novartis | Jun 2007 | 80 |
| NCT00171860Hypereosinophilic Syndrome · Belgium | 2 | Terminated | Novartis | Jul 2007 | 24 |
| NCT00171249Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, France, Germany and more | 2 | Completed | Novartis | Sep 23, 2013 | 293 |
| NCT00171223Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, France, Germany and more | 2 | Completed | Novartis | Nov 29, 2013 | 532 |
| NCT00171158Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, France, Germany and more | 2 | Completed | Novartis | Apr 2013 | 260 |
| NCT00154388Adenocarcinoma | 2 | Completed | Novartis | Jan 2007 | 185 |
| NCT00154375Glioblastoma · Germany | 3 | Completed | Novartis | Aug 2008 | 240 |
| NCT00154349Philadelphia Chromosome Positive Acute Lymphocytic Leukemia | 2 | Completed | Novartis | Feb 2007 | 8 |
| NCT00154336Arthritis, Rheumatoid · Austria, Canada, Finland and more | 2 | Completed | Novartis | Aug 2005 | 50 |
| NCT00150072Chordoma · Italy, Switzerland | 2 | Completed | Novartis | Apr 2008 | 55 |
| NCT00124748Leukemia, Myeloid, Chronic-Phase · United States, Argentina, Australia and more | 3 | Terminated | Novartis | Nov 2010 | 476 |
| NCT00093639Leukemia · United States | 2 | Completed | Novartis | Aug 2006 | |
| NCT00081926Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States | 4 | Completed | Novartis | 112 | |
| NCT00006475Leukemia · United States | 2 | Completed | Novartis | Dec 2002 | |
| NCT00006053Leukemia · United States | 2 | Completed | Novartis | Mar 2003 |
How it is read
Names in the registry
- “Imatinib”, 18 entries
- “imatinib mesylate”, 15 entries
- “Imatinib mesylate”, 6 entries
- “Imatinib Mesylate”, 5 entries
- “imatinib”, 4 entries
Conditions, from the studies’ own filings
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 20 studies
- Gastrointestinal Stromal Tumors, 13 studies
- Pulmonary Arterial Hypertension, 6 studies
- Leukemia, Myeloid, Chronic-Phase, 3 studies
- Glioblastoma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.